tiprankstipranks
Trending News
More News >
Opthea Limited (AU:OPT)
ASX:OPT
Advertisement

Opthea (OPT) Price & Analysis

Compare
44 Followers

OPT Stock Chart & Stats


Opthea News

OPT FAQ

What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.59 and its highest was AU$1.17 in the past 12 months.
    What is Opthea Limited’s market cap?
    Opthea Limited’s market cap is $738.77M.
      When is Opthea Limited’s upcoming earnings report date?
      Opthea Limited’s upcoming earnings report date is Feb 26, 2026 which is in 141 days.
        How were Opthea Limited’s earnings last quarter?
        Opthea Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of -AU$0.013 by -AU$0.027.
          Is Opthea Limited overvalued?
          According to Wall Street analysts Opthea Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Opthea Limited pay dividends?
            Opthea Limited does not currently pay dividends.
            What is Opthea Limited’s EPS estimate?
            Opthea Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Opthea Limited have?
            Opthea Limited has 1,367,978,100 shares outstanding.
              What happened to Opthea Limited’s price movement after its last earnings report?
              Opthea Limited reported an EPS of -AU$0.04 in its last earnings report, missing expectations of -AU$0.013. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Opthea Limited?
                Currently, no hedge funds are holding shares in AU:OPT

                Company Description

                Opthea Limited

                Opthea Limited (OPT) is a biotechnology company focused on developing treatments for eye diseases. The company operates primarily in the healthcare sector, with its core product being OPT-302, a novel therapy intended for the treatment of wet age-related macular degeneration (wet AMD) and other retinal vascular disorders. Opthea's mission is to enhance vision care by pioneering innovative therapies that address unmet medical needs in ophthalmology.

                Opthea (OPT) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Immutep Ltd
                Dimerix Limited
                Race Oncology Ltd.
                Clarity Pharmaceuticals Ltd.
                Botanix Pharmaceuticals Limited

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis